UPDATE: World Heart CFO on layoffs, future plans

February 24, 2012 By MassDevice staff Leave a Comment

A skeleton crew of 6 employees at World Heart Corp. (NSDQ:WHRT) will push ahead with the development of its MiFlow heart pump despite layoffs for 77% of their colleagues, CFO Morgan Brown told MassDevice.com this morning.

The Salt Lake City-based firm said yesterday that it laid off 19 full-time workers and 1 part-time employee in an effort to hoard cash while it explores "various corporate strategic options." The layoffs, made across all departments, include its chief technology officer, John Woodard, effective today, according to a regulatory filing.

Brown said the layoffs will allow World Heart to continue operating while it explores its options, which might include a joint venture, a co-development deal, a merger or an acquisition. In the meantime, he said, the company is still working on the MiFlow device, an adult-sized version of its PediaFlow cardiac assist device.

"The bottom line is that we continue to push that program forward, obviously with fewer people," Brown told us, adding that World Heart will focus on developing the pump itself, as opposed to peripherals such as a controller or batteries. "We still have plenty of cash, in excess of $9 million as of the end of the year. Especially since we’ve cranked down our burn with this most recent announcement, if we wanted to put it on a slow drip we could keep it alive for the next several years. This was meant to allow us to have greater flexibility to evaluate options and create a longer timeline for that to happen."

Losing Woodard won’t affect the MiFlow program, he said.

"We’ve kept our vice president of R&D, who really is the detailed technical team leader on the MiFlow program, so it doesn’t affect anything at all," Brown said.

As for the proverbial "strategic options" the company is looking into, World Heart is shopping itself to potential suitors, he said.

"The landscape’s fairly narrow. We know who the players are," Brown told us.

World Heart said the move is expected to cost between $965,000 and $1.1 million, with about $860,000 coming due during the 1st and 2nd quarters and the remainder over the rest of the year.

Last summer the company cut 21 employees, nearly half of its workforce, and halted clinical trials of its Levacor ventricular assist device. That prompted its shares to slip below the $1 apiece mark, triggering a warning from the NASDAQ stock exchange of a potential de-listing as of Feb. 13, 2012.

But earlier this month, NASDAQ gave World Heart a 6-month de-listing reprieve, giving the company another 6 months to boost its share price above the $1 requirement. The new deadline is August 13.

When the original layoffs were announced, Brown told us that the decision to leave the Levacor device on the table came after conversations with the FDA made it apparent that the timeline to approval was longer than expected.

“It became increasingly clear that as we went down process timelines we were hoping for were not going to be achieved and we were going to be delayed significantly,” Brown told us at the time.

WHRT shares were trading at 22 cents as of about 11:45 this morning, down 18.4%.

5 tips to raise funding for your medical device
Securing funding can be a long and tedious process, and medical device businesses must work to position themselves as especially attractive to potential investors to maximize success and accelerate the fundraising process. Jon Speer, Greenlight Guru According to Alejandro Cremades, author of The Art of Startup Fundraising, it can take from six to nine months… […]
FDA recognizes latest ISO 14971 as medical device consensus standard
By Mark Leimbeck and Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted Recognized Consensus Standard status to the third edition of the ISO 14071 risk management standard for medical devices and IVD products. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are… […]
Synaptive Medical updates Modus V surgical microscope
Synaptive Medical announced that its U.S. and Canadian Modus V robotic digital microscope now includes updates such as additional 3D visualization and voice-activated control. The Modus V is a robotically controlled digital microscope used as part of Synaptive’s BrightMatter surgical suite designed for less invasive, patient-specific approaches in complex cranial procedures. The Modus V provides similar… […]
New machine can preserve donor livers for 1 week
Researchers in Switzerland have built a perfusion machine that can preserve human livers for transplantation for a week or more, potentially slashing the number of donor livers that must be discarded due to time-related deterioration. Existing perfusion technology can preserve a donor liver for up to 24 hours. The team of surgeons, biologists and engineers… […]
Smiths Medical launches Portex tracheostomy tubes and kits
Smiths Medical this week launched its Portex polyvinyl chloride tracheostomy tube and kit portfolio. The new polyvinyl chloride (PVC) tube portfolio has options for a variety of patients, according to the company. “Our goal was to create tracheostomy tubes and kits designed to help clinicians provide the best patient care. We’re excited to offer a variety… […]
FDA clears Cleveland Clinic 3D-printed airway stents
The FDA recently cleared 3D-printed, patient-specific stents developed by a doctor at the Cleveland Clinic. Cleveland Clinic physician Tom Gildea developed the stents to keep open the airways of patients with serious breathing disorders caused by inflammation, trauma, tumors and other masses. Airway stents come in a limited number of sizes and shapes and are… […]
Boston Scientific shares drop on Q4 sales news
Shares in Boston Scientific (NYSE:BSX) dropped 8% this morning on news of disappointing fourth-quarter sales. The company’s preliminary earnings report showed sales for the quarter ended Dec. 31, 2019 coming in at $2.9 billion, below the $2.91 billion that analysts were expecting. The unaudited sales figure represents organic growth of 7.3%, missing the company’s own guidance of… […]
Study: Timing for knee replacement surgeries is off
New research from Northwestern Medicine suggests that patients with knee osteoarthritis are having knee surgery at the wrong time. According to the researchers, 90% of patients who could benefit from knee replacement surgery are waiting too long to have it and 25% of patients who don’t need it are having it prematurely. “People are waiting… […]
TransEnterix wants to use more AI in surgical robotics: Here’s how
TransEnterix (NYSE:TRXC) has filed a 510(k) submission to add an artificial intelligence feature to its robot-assisted surgery system in which the system can automatically move the camera for a surgeon. Surgeons have been able to move the camera on TransEnterix’s Senhance System via eye sensing. But the new Intelligent Surgical Unit would allow a surgeon, for… […]
Diversified Plastics names Kieval to board
Diversified Plastics, a custom plastic-injection molder and digital thermoplastic components manufacturer, said today that it has appointed Robert Kieval to its board of directors. Kieval has more than 25 years of experience at all levels of the medtech industry. The CEO of IMMR, Inc., Kieval previously served as chief scientific and clinical officer at women’s… […]
Micro celebrates 75 years in business
Contract manufacturer Micro (Somerset, N.J.) this week announced its 75th anniversary in business. Founded in 1945 as Micro Stamping Corp. in Maplewood, N.J., the family-owned company specializes in precision medical components, sub-assemblies and complete devices for laparoscopic surgical procedures. Operations have expanded from 28,000-square feet to nearly 180,000-square feet, and the company recently dedicated an… […]